Itay Mayer, Vice President and Managing Director of Lumenis Vision, caught up with Optometry Times® to share an update on the company and its products, which was showcased during the 2023 Vision Expo East meeting in New York, New York.
The Business of Dry Eye: 4 Steps to Boosting Practice Profitability with In-Office Treatments
Researchers found that 20 tear cytokines decreased significantly after IPL treatment, illustrating how IPL suppresses DED’s vicious cycle of inflammation.
Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye
Researchers found that 20 tear cytokines decreased significantly after IPL treatment, illustrating how IPL suppresses DED’s vicious cycle of inflammation.
Three Ways OptiLight Is Changing Dry Eye Management in Our Practice
Drs. Rachna Murthy and Jonathan Roos tapped into OptiLight to revolutionize their dry eye management services, addressing patient pathology and rejuvenating their appearance
Significantly Improved Signs of Dry Eye Disease: Key Findings from FDA Study of Lumenis Light Therapy
The strongest affirmation of safety and efficacy- Dr. Steven Dell shares clinical benefits of Lumenis dry eye light therapy that…
Mandy Moore Opens Up About Her Experience With Dry Eyes—’I Figured the Discomfort Was Something I Was Just Going to Have to Live With’
OptiLight to the Rescue: Mandy Moore shares her story of being diagnosed with dry eye, and the solution she discovered to treat the painful symptoms that were negatively impacting her daily life.
Elevating Patient Care: OptiLight Insights and Case Studies
Insights and case studies from Dr. Kambiz Silani at Beverly Hills Optometry show how OptiLight helps elevate patient care.
Four Tips for Implementing OptiLight and Optimizing ROI
As Dr. Richard Adler explains, doctors control their own success with OptiLight, from changes in dry eye philosophy, to improved communication, to novel marketing strategies.
Toyos et al. (2022) Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study
The US FDA approval for Lumenis IPL with OPT™ for management of DED was based on this recent clinical study.
In this perspective, multi-center, double-blinded, randomized controlled study, Lumenis IPL with OPT™ combined with MGX significantly improved signs of DED due to MGD in patients with moderate to severe symptoms.
How I Tripled My Dry Eye Revenues
Six months after purchasing OptiLight and focusing his practice on dry eye, Shane Swatts, OD, has tripled revenues, and he’s enjoying his work more than ever.